Arrowhead Pharmaceuticals, Inc.
ARWRNext catalyst
ARO-ALK7
Obesity
Get an email about ARWR's next catalysts
Track Arrowhead Pharmaceuticals (ARWR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 5 more upcoming events in our data (earnings, Phase 2 readout, Phase 3 readout).See the timeline
6 upcoming, 0 past
ARWR Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.59 | FQ end Sep/2026 | Call: tbd
ARO-ALK7 Phase 2 Est. Readout
Primary completion for ARO-ALK7 trial (NCT06937203) in Obesity
SourceARO-MAPT-SC Phase 2 Est. Readout
Primary completion for ARO-MAPT-SC trial (NCT07221344) in Alzheimer Disease
SourceARO-DIMERPA Phase 2 Est. Readout
Estimated primary completion for ARO-DIMERPA trial (NCT07223658) in Hyperlipidemia; Mixed. Topline data typically follows completion by weeks to months.
Sourcezodasiran Injection Phase 3 Est. Readout
Primary completion for zodasiran Injection trial (NCT07037771) in Homozygous Familial Hypercholesterolemia
SourceARO-INHBE Phase 2 Est. Readout
Estimated primary completion for ARO-INHBE trial (NCT06700538) in Obesity. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
Websitezodasiran Injection
Homozygous Familial Hypercholesterolemia
Plozasiran
Familial Chylomicronemia
Zodasiran
Homozygous Familial Hypercholesterolemia
Plozasiran Injection
Severe Hypertriglyceridemia
ARO-APOC3
Mixed Dyslipidemia
ARO-MAPT-SC
Alzheimer Disease
ARO-INHBE
Obesity
ARO-HSD Injection
Non-alcoholic Steatohepatitis
ARO-AAT
Alpha 1-Antitrypsin Deficiency
ARO-C3
C3 Glomerulopathy
ARO-ALK7
Obesity
ARO-HBV
Hepatitis B
ARO-RAGE
Asthma
Fazisiran Injection
Alpha 1-Antitrypsin Deficiency
ARO-ANG3
Mixed Dyslipidemia
ARO-ANG 3 Injection
Homozygous Familial Hypercholesterolemia
ARO-DUX4 for Injection
Facio-Scapulo-Humeral Dystrophy
ARO-DIMERPA
Hyperlipidemia; Mixed
JNJ-56136379
Hepatitis B
ARO-DM1 Intravenous (IV) Infusion
Myotonic Dystrophy 1
ARO-CFB
IgA Nephropathy
ARO-MMP7 Inhalation Solution
Idiopathic Pulmonary Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
zodasiran Injection | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Plozasiran | Phase 3 | Familial Chylomicronemia | - | - |
Zodasiran | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Plozasiran Injection | Phase 3 | Severe Hypertriglyceridemia | - | - |
ARO-APOC3 | Phase 2 | Mixed Dyslipidemia | - | - |
ARO-MAPT-SC | Phase 2 | Alzheimer Disease | - | - |
ARO-INHBE | Phase 2 | Obesity | - | - |
ARO-HSD Injection | Phase 2 | Non-alcoholic Steatohepatitis | - | - |
ARO-AAT | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
ARO-C3 | Phase 2 | C3 Glomerulopathy | - | - |
ARO-ALK7 | Phase 2 | Obesity | - | - |
ARO-HBV | Phase 2 | Hepatitis B | - | - |
ARO-RAGE | Phase 2 | Asthma | - | - |
Fazisiran Injection | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
ARO-ANG3 | Phase 2 | Mixed Dyslipidemia | - | - |
ARO-ANG 3 Injection | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
ARO-DUX4 for Injection | Phase 2 | Facio-Scapulo-Humeral Dystrophy | - | - |
ARO-DIMERPA | Phase 2 | Hyperlipidemia; Mixed | - | - |
JNJ-56136379 | Phase 2 | Hepatitis B | - | - |
ARO-DM1 Intravenous (IV) Infusion | Phase 2 | Myotonic Dystrophy 1 | - | - |
ARO-CFB | Phase 2 | IgA Nephropathy | - | - |
ARO-MMP7 Inhalation Solution | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Arrowhead Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 22 drug candidates in Arrowhead Pharmaceuticals, Inc.'s (ARWR) pipeline across Phase 3, Phase 2. Its lead program is zodasiran Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arrowhead Pharmaceuticals, Inc.'s next FDA catalyst?→
Arrowhead Pharmaceuticals, Inc.'s (ARWR) next tracked catalyst is a Phase 2 readout expected February 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARWR biotech catalysts?→
Add ARWR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arrowhead Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.